Dutch Court Grants Novo Nordisk Preliminary Injunction in Semaglutide Nasal Spray Patent Dispute
Written By : sheeba farhat
Published On 2026-08-07 15:20 GMT | Update On 2026-08-07 15:20 GMT
Stockholm: Novo Nordisk said on Wednesday it had won a preliminary injunction against Ceban Ziekenhuisfarmacie from a district court in the Netherlands in a patent infringement case involving a compounded semaglutide nasal spray.
Semaglutide is the active ingredient in Novo Nordisk's weight-loss drug Wegovy.
"The Court found that Ceban infringed Novo Nordisk's supplementary protection certificate (SPC) covering semaglutide," the Danish drugmaker said in a statement.
It said the court ordered Dutch firm Ceban to cease the infringing activities, remove product listings, disclose supply chain information, and reimburse Novo Nordisk's legal costs.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.